Climb Financial Statements From 2010 to 2026

CLYM Stock   3.75  0.25  6.25%   
Climb Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Climb Bio's valuation are provided below:
Market Capitalization
255.7 M
Earnings Share
(0.59)
There are over one hundred six available fundamental signals for Climb Bio, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to validate Climb Bio's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 4th of January 2026, Market Cap is likely to grow to about 104.4 M, though Enterprise Value is likely to grow to (3.3 K).
Check Climb Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Climb Bio's main balance sheet or income statement drivers, such as Selling General Administrative of 13.8 M, Other Operating Expenses of 99 M or Research Development of 17 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.45. Climb financial statements analysis is a perfect complement when working with Climb Bio Valuation or Volatility modules.
  
Build AI portfolio with Climb Stock
Check out the analysis of Climb Bio Correlation against competitors.
To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.

Climb Bio Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets125 M249.8 M73.5 M
Slightly volatile
Other Current Liabilities3.4 M4.7 M1.6 M
Slightly volatile
Total Current Liabilities4.4 M5.7 M2.4 M
Slightly volatile
Total Stockholder Equity255.8 M243.7 M79 M
Slightly volatile
Accounts Payable621.1 K634.5 K690.4 K
Very volatile
Cash57.3 M100.3 M38.9 M
Slightly volatile
Non Current Assets Total75.2 M71.7 M14 M
Slightly volatile
Non Currrent Assets Other183.8 K193.5 K268.1 K
Pretty Stable
Cash And Short Term Investments102.6 M173.6 M60.4 M
Slightly volatile
Common Stock Shares Outstanding58.2 M55.4 M20.9 M
Slightly volatile
Liabilities And Stockholders Equity125 M249.8 M73.5 M
Slightly volatile
Other Current Assets2.7 M3.3 M1.3 M
Slightly volatile
Other Stockholder Equity533.4 M508 M133 M
Slightly volatile
Total Liabilities4.5 M6.1 M2.5 M
Slightly volatile
Total Current Assets108.4 M178.1 M62.9 M
Slightly volatile
Common Stock8.5 K8.1 K2.6 K
Slightly volatile
Capital StockK6.3 K30.1 M
Slightly volatile
Net Working Capital120.3 M172.4 M60.5 M
Slightly volatile
Net Receivables956.7 KM5.3 M
Slightly volatile
Non Current Liabilities Other15.9 K25.3 K11.2 K
Slightly volatile
Short and Long Term Debt Total499 K611.8 K484.2 K
Pretty Stable
Short Term Debt210.9 K141.3 K279 K
Slightly volatile

Climb Bio Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative13.8 M18.4 M6.7 M
Slightly volatile
Other Operating Expenses99 M94.3 M28.9 M
Slightly volatile
Research Development17 M16.5 M9.5 M
Slightly volatile
Total Operating Expenses99 M94.3 M28.9 M
Slightly volatile
Net Interest Income5.2 M9.4 M2.7 M
Slightly volatile
Interest Income5.2 M9.4 M2.7 M
Slightly volatile

Climb Bio Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Cashflows From Financing Activities9.4 M9.9 M23.1 M
Pretty Stable
End Period Cash Flow57.3 M100.3 M38.9 M
Slightly volatile
Stock Based Compensation6.6 M6.4 M2.9 M
Slightly volatile
Begin Period Cash Flow112.4 M107.1 M38.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
PTB Ratio0.450.473.1765
Slightly volatile
Book Value Per Share4.073.963.2041
Slightly volatile
PB Ratio0.450.473.1765
Slightly volatile
Cash Per Share3.542.822.8961
Slightly volatile
Income Quality0.230.240.6579
Slightly volatile
Net Debt To EBITDA2.513.283.5385
Slightly volatile
Current Ratio20.1828.2726.1409
Very volatile
Tangible Book Value Per Share4.073.963.2041
Slightly volatile
Shareholders Equity Per Share4.073.963.2041
Slightly volatile
Debt To Equity0.00350.00290.0036
Slightly volatile
Graham Net Net3.452.742.8149
Slightly volatile
Interest Debt Per Share0.01550.01270.017
Slightly volatile
Debt To Assets0.00340.00280.0034
Slightly volatile
Price Book Value Ratio0.450.473.1765
Slightly volatile
Ebt Per Ebit1.11.040.9427
Slightly volatile
Company Equity Multiplier1.161.181.0587
Slightly volatile
Total Debt To Capitalization0.00350.00290.0036
Slightly volatile
Debt Equity Ratio0.00350.00290.0036
Slightly volatile
Quick Ratio20.1828.2726.1409
Very volatile
Cash Ratio13.2415.9221.9048
Slightly volatile
Price To Book Ratio0.450.473.1765
Slightly volatile
Debt Ratio0.00340.00280.0034
Slightly volatile
Price Fair Value0.450.473.1765
Slightly volatile

Climb Bio Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap104.4 M78 M105.1 M
Slightly volatile

Climb Fundamental Market Drivers

About Climb Bio Financial Statements

Climb Bio investors utilize fundamental indicators, such as revenue or net income, to predict how Climb Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Climb Bio is a strong investment it is important to analyze Climb Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Climb Bio's future performance. For an informed investment choice regarding Climb Stock, refer to the following important reports:
Check out the analysis of Climb Bio Correlation against competitors.
To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.
You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.59)
Return On Assets
(0.17)
Return On Equity
(0.26)
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.